Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.
Latest Ratings for OMER
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Oct 2021 | JP Morgan | Downgrades | Neutral | Underweight |
| Oct 2021 | HC Wainwright & Co. | Maintains | Buy |
